Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,140 | 0,141 | 12:56 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | GenSight Biologics Reports Cash Position as of September 30, 2025 | 234 | Business Wire | Cash position amounted to €0.6 million as of September 30, 2025
Successful closing of fundraising worth nearly EUR3.7 million on October 1, 2025
Cash position amounted to €3.6 million... ► Artikel lesen | |
01.10. | GenSight Biologics S.A.: GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million | 326 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
GENSIGHT BIOLOGICS Aktie jetzt für 0€ handeln | |||||
29.09. | GenSight Biologics Reports Interim Financial Results for the First Half of 2025 | 356 | Business Wire | Optimized cash management results in 8.3% reduction in operating cash outflow compared to the same period in 2024
Cash runway extended to late Q4 2025 following post-closing financing
... ► Artikel lesen | |
26.09. | GenSight Biologics S.A.: GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million | 201 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
28.08. | GenSight Biologics S.A.: GenSight Biologics Postpones Release of 2025 Half-Year Financial Results | 358 | Business Wire | Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing... ► Artikel lesen | |
22.07. | GenSight Biologics Announces the Closing of Approximately €500,000 of Additional Financing | 374 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
17.07. | GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ Gene Therapy | 302 | Business Wire | Better baseline visual acuity and thicker baseline optical coherence tomography (OCT) parameters predict better final visual outcome
Patients treated during dynamic phase achieve better... ► Artikel lesen | |
17.07. | GenSight Biologics Raises Approx. EUR 500K | 2 | FinSMEs | ||
17.07. | GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder | 414 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
08.07. | GenSight Biologics Reports Cash Position as of June 30, 2025 | 384 | Business Wire | Operations funded until early October 2025 as a result of disciplined spending controls
Agreement with the ANSM to consider opening the Named Early Access Program (AAC) for LUMEVOQ in France... ► Artikel lesen | |
03.07. | GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement | 442 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
01.07. | GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million | 431 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
GenSight Biologics (the "Company") (Euronext: SIGHT... ► Artikel lesen | |
26.06. | GenSight Transfers Upstream Phase of LUMEVOQ Manufacturing Process to Catalent | 3 | Contract Pharma | ||
26.06. | GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent | 341 | Business Wire | Upstream phase of LUMEVOQ manufacturing process successfully transferred
Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and... ► Artikel lesen | |
12.06. | GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ Named Early Access Program (AAC) in France | 509 | Business Wire | Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study
Design for dose-ranging study submitted, with clinical trial application... ► Artikel lesen | |
13.05. | GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025 | 402 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing... ► Artikel lesen | |
23.04. | GenSight Biologics Annual General Meeting on May 13, 2025 | 543 | Business Wire | Procedures for obtaining preparatory documents for the General Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused... ► Artikel lesen | |
08.04. | GenSight Biologics S.A.: GenSight Biologics Announces the Filing of its 2024 Universal Registration Document | 468 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
07.04. | GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update | 436 | Business Wire | Operations funded until early June 2025 as a result of disciplined spending controls
Discussions with French agency ANSM regarding the early access program (AAC) for LUMEVOQ progressing
... ► Artikel lesen | |
19.03. | GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates | 489 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 89,45 | +1,82 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
EVOTEC | 6,690 | -0,12 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
BB BIOTECH | 40,700 | -0,25 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
MEDIGENE | 0,062 | -0,32 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
QIAGEN | 40,505 | +0,09 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
CUREVAC | 4,642 | +0,26 % | CureVac-Aktie am Scheideweg: Explodiert der Kurs jetzt - oder droht der völlige Absturz?! Anleger in Alarmbereitschaft!!! | ||
MODERNA | 23,405 | +1,92 % | Moderna, Inc.: Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress | mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety... ► Artikel lesen | |
PAION | 0,017 | -23,21 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
VALNEVA | 4,512 | +0,85 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
AMGEN | 251,10 | +0,46 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
EPIGENOMICS | 0,884 | +0,23 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
NOVAVAX | 7,237 | +0,95 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
STRYKER | 316,40 | +0,76 % | Stryker to roll out training center model in Ireland with first in Limerick | ||
BIOGEN | 127,25 | +0,79 % | Biogen - BIIB: Leqembi erhält Zulassungen in China & Australien! | Pullback-Setup mit Bullenflagge! Neuausrichtung bei Biogen (BIIB): Alcyone Therapeutics für rund 85 Millionen USD übernommen & Rückzug aus AAV-basierten Gentherapieprojekten! Biogen (BIIB) - ISIN US09062X1037... ► Artikel lesen | |
BIOFRONTERA | 2,710 | 0,00 % | BIOFRONTERA AG: Jetzt zündet die nächste Kursrakete! |